FiercePharma provides news and information related to the pharmaceutical industry, including topics like vaccines, drug delivery, and manufacturing, self-described as highlighting corporations driving change in healthcare.

FiercePharma

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Scott Glenn

Lauren G. Otsuki

Oncternal Therapeutics, Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Kyung Ae Lee

Thomas A Wynn

Christina Warren

Pfizer Inc.

TEDMED hosts talks and conferences focused on health and medicine. The platform features various playlists and speakers addressing diverse topics related to health.

Metric
Company Name	FiercePharma	Oncternal Therapeutics, Inc.	Pfizer Inc.	TEDMED
Symbol		ONCT	PFE
MSH ID	COM:FIERCEPHARMA	COM:ONCTERNAL	COM:PFIZER	COM:TEDMED
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Commercial & Professional Services	Healthcare	Healthcare	Healthcare & Health Services
Industry	Pharmaceuticals	Biotechnology	Drug Manufacturers - General	Health Communication
Country	US	US	US	US
Stage
Employee Count		27	88K
Website	fiercepharma.com	oncternal.com	pfizer.com	tedmed.com
LinkedIn		oncternal-therapeutics	pfizer
Founders

Metric
Market Cap		21.66M	160.65B
Enterprise Value
Monthly Web Traffic	484.53K		1.84M
Web Traffic Growth	-0.10		0.15
Valuation
Raised Capital			1B

Metric
Revenue	785K	58.50B
Revenue (LTM)
Revenue (NTM)
Gross Profit	785K	29.28B
EBITDA	-41.71M	10.53B
Operating Income	-41.71M	4.24B
Net Income	-39.48M	2.12B
EPS	-13.43	0.38
Diluted EPS	-13.43	0.38
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.81	0.52
Operating Profit Margin	-20.41	0.06
EBITDA Margin	-53.14	0.18
Net Profit Margin	-19.49	0.04
Return on Equity	1.20	0.02
Return on Assets	-1.07	0.01
Return on Capital Employed	-1.32	5.56

COM:FIERCEPHARMA

FiercePharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-13.60	14.35
P/B Ratio	-2.97	1.55
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	33.89	3.21
EV Multiple	-0.25	17.74

Metric
Days Sales Outstanding		79.90
Days Payables Outstanding		72.06
Days Inventory Outstanding	0.00	155.46
Operating Cycle	293.86	230.19
Cash Conversion Cycle	232.41	160.85
Asset Turnover	0.08	141.27

Metric
Operating Cash Flow	-32.16M	8.70B
Free Cash Flow	-32.16M	4.79B
Cash Flow to Debt		0.12
Operating Cash Flow/Sales	-13.65	0.16
Free Cash Flow Yield	-1.24	0.05

Metric
Cash & Equivalents	6.70M	2.85B
Accounts Receivable		347M
Inventory		10.19B
Goodwill		67.78B
Debt to Capitalization	0.01	0.45
Debt to Assets	0.01	0.30
Current Ratio	8.25	2.38
Quick Ratio	6.71	94.70

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.01
R&D to Revenue			0.17
SG&A to Revenue